Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a 5% increase in stock price, reaching 42.63 yuan per share, with a total market capitalization of 7 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - According to data, Dachen Fund has a significant holding in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 23.45% and a one-year return of 46.55% [2] - The fund manager, Zou Jian, has been in position for 4 years and 243 days, with the fund's total asset size currently at 1.086 billion yuan [2]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a significant stock price increase of 5.18%, reaching 39.00 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 4.34%, resulting in a total market capitalization of 6.404 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main business revenue composition being 49.07% from film-coated rubber stoppers, 48.50% from conventional rubber stoppers, and 2.43% from other products [1] Group 2 - From the perspective of fund holdings, Dachen Fund has a significant position in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value, making it the eighth largest holding [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 25.08% and a one-year return of 45.68%, ranking 3502 out of 8172 and 3660 out of 7980 respectively in its category [2] - The fund manager, Zou Jian, has been in position for 4 years and 236 days, with the fund's total asset size being 1.086 billion yuan, and the best and worst returns during his tenure being 13.52% and -21.29% respectively [2]

2025年8月27日，华兰股份(301093.SZ)发布2025年半年度报告。截至2025年8月26日，共有10个机构投 资者披露持有华兰股份A股股份，合计持股量达5660.92万股，占华兰股份总股本的44.82%。其中，前 十大机构投资者包括江阴华兰机电科技有限公司、瑞众人寿保险有限责任公司-自有资金、上海磬晟私 募基金管理有限公司-磬晟联盈五号私募证券投资基金、江阴华恒投资有限公司、和盛财富(北京)基金管 理有限公司-和盛财富甄选七号私募证券投资基金、中国银河证券股份有限公司、长江智能制造混合型 发起式A、大成创业板两年定开混合A、银河康乐股票A、长江旭日混合A，前十大机构投资者合计持股 比例达44.82%。相较于上一季度，前十大机构持股比例合计下跌了4.34个百分点。 公募基金方面本期较上一季度持股减少的公募基金共计3个，包括长江智能制造混合型发起式A、长江 旭日混合A、银河康乐股票A，持股减少占比达0.26%。本期较上一季度新披露的公募基金共计1个，即 大成创业板两年定开混合A。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 对于社保基金，本期较上一季未再披露的社保基金共计1 ...

险资方向，本期较上一期持股增加的险资共计2个，包括前海人寿保险股份有限公司-分红保险产品华泰 组合、前海人寿保险股份有限公司-分红保险产品，持股增加占比达0.2%。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 2025年8月9日，三鑫医疗(300453.SZ)发布2025年半年度报告。截至2025年8月08日，共有7个机构投资 者披露持有三鑫医疗A股股份，合计持股量达3422.78万股，占三鑫医疗总股本的6.55%。其中，机构投 资者包括前海人寿保险股份有限公司-分红保险产品华泰组合、前海人寿保险股份有限公司-分红保险产 品华泰组合、前海人寿保险股份有限公司-分红保险产品、前海人寿保险股份有限公司-分红保险产品、 大成创业板两年定开混合A、诺安主题精选混合、汇安资产轮动混合A，机构投资者合计持股比例达 6.55%。相较于上一季度，机构持股比例合计上涨了1.00个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即汇安资产轮动混合A，持股增加占比小 幅上涨。本期较上一季度新披露的公募基金共计2个，包括大成创业板两年定开混合A、诺安主题精选 混合。本期较上一季未再披露的公 ...